STOCKS TELEGRAPH

Tag: Inc

  • Beyond Meat, Inc. (BYND) stock Gains in Pre-Market Today: Why is it so?

    Beyond Meat, Inc. (BYND) stock Gains in Pre-Market Today: Why is it so?

    Beyond Meat, Inc. (BYND) announced the opening of Plant-based meat manufacturing facility in China after which BYND’s stock price was pushed by 2.65% in the pre-market session to reach $137.50 a  share at the time of this writing. BYND outperformed at the previous trading session and closed with a 1.79% gain. Let’s look at current events in detail.

    Plant-Based Meat Manufacturing Facility:

    Beyond Meat, Inc. (BYND) is a food company working as the manufacturer, marketer, and seller of plant-based meat products in the U.S and the globe. The main purpose of the world-class plant-based meat manufacturing facility in the Jiaxing Economic & Technological Development Zone (JXEDZ) near Shanghai is to fasten the local production as well as innovation. This development would help Beyond Meat stock to expand its network in the Jiaxing by speedy manufacturing and distribution of its products within the region. Furthermore, this step would strengthen the cost structure of BYND stock and would provide sustainability to the operations.

    Future growth:

    This facility will produce a variety of plant-based meat products which include plant-based pork, poultry products, and beef. Beyond Pork which, is specially created for the Chinese market, is also added to this facility. The facility will help BYND in the research and development of new and unique plant-based meat products and will support its local strategic partners.BYND stock is making serious efforts in the advancement of plant-based meat products in China for long-term growth.

    Beyond Meat Position in China:

    About a year ago, BYND signed an agreement with Starbucks China and within the year, BYND stock had expanded menu offerings at Starbucks and did partnerships with many of the renowned brands like KFC, Pizza Hut, Jindingxuan, and many more. Moreover, Beyond Meat has successfully built its reputation among the local consumers in China who prefer a healthy and sustainable lifestyle.

    Conclusion:

    Investors are responding to the news related to the opening of a new plant-based meat manufacturing facility announced by BYND stock. This development of BYND stock would pave the way to the long-term growth of Beyond Meat in China. Hence BYND stock can be a good bet for investors having long-term prospects.

  • Why 9 Meters Biopharma, Inc. (NMTR) stock is gaining in Pre-Market today?

    Why 9 Meters Biopharma, Inc. (NMTR) stock is gaining in Pre-Market today?

    9 Meters Biopharma, Inc. (NMTR) stock was green in the pre-market trading session after suffering the drop of 4.31% at the previous closing. NMTR stock price saw a push of 13.51% to reach $1.26 a share at the time of this writing. There is no particular activity related to NMTR stock in today’s date however, 9 Meters stock on April 5, 2021, announced the closing of an offering of its common stock. Let’s deep dive to explore more of it.

    What’s happening?

    NMTR recently announced the closing of an offering of  34,500,000 shares of its common stock including additional sales of shares by underwriters at the public price of $1.00 a share. The offering was initiated on March 30, 2021, in which underwriters were granted the 30-day option to sell additional 4,500,000 shares of the common stock of NMTR. The gross proceeds were expected $30 million at that time without deducting the underwriting discounts and offering related expenses while the net proceeds resulted from these offerings after deducting underwriters’ discounts and other expenses were recorded at approximately 31.5 million at the closing of the offering.

    Financial View of NMTR stock:

    On March 22, 2021, NMTR announced its fourth quarter and full-year 2020 financial results according to which 9 Meter bore $5.0 million or $0.03 per share net loss in the fourth quarter of 2020 as compared to $8.5 million or $0.25 per share net loss in the same quarter of the previous year. For the full fiscal year 2020, the net loss of NMTR stock was  $61.5 million or $0.58 per while it was $27.0 million or $0.81 per share in 2019.

    As of December 31, 2020, NMTR had cash and cash equivalents of $37.9 million which were significantly higher than the $4.6 million cash and cash equivalents at the end of 2019. As of March 19, 2021, NMTR generated additional proceeds of $6.7 million from warrant exercises.

    Conclusion:

    It seems that NMTR stock is hot among investors today, but it would be interesting to see how long this trend would persist in the future.Net proceeds were recorded more than the expected gross proceeds from the offering of NMTR stock. The financial report tells that 9 Meter has increased the value of its assets over the year. In short, investors should keep an eye on this stock.

  • Phunware, Inc. (PHUN) stock is popping high today: Why is it so?

    Phunware, Inc. (PHUN) stock is popping high today: Why is it so?

    Shares of Phunware, Inc. (PHUN) stock were popping high today after the spread of the news that Phunware board of directors has authorized the Bitcoin purchases for the launch of the Blockchain ecosystem after which the PHUN stock price saw a push of  25.58% to reach $2.16 a share at the time of this writing.PHUN stock seemed green at the previous trading session and closed with a 6.17% gain. Let’s have a look at current events.

    What’s happening?

    Phunware, Inc is the provider of an integrated software platform to brands worldwide to monetize their mobile application portfolios.PHUN’s board of directors has authorized the Bitcoin purchases for the launch of its Maas Customer Data Platform and Maas Mobile Loyalty Ecosystem both of which are equipped with Blockchain technology.

    PHUN stock is expected to release its mobile application PhunWallet on both iOS and android soon this month after getting approvals from Apple App Store and Google Play Store.PhunWallet will reward consumers PhunCoin and PhunToken for the value of their data and engagement, respectively.

    Recent Developments:

    According to the management, Phunware recently completed the purchase of 25.8 bitcoin at an average price of $58,133 per bitcoin. PHUN stock has recently signed an agreement with BitPay in order to expand its corporate benefits package. Employees would be provided cryptocurrency payroll options including Bitcoin, in connection with this agreement.

    Financial View of PHUN stock:

    On March 26, 2021, Phunware stock announced the fourth quarter and full-year 2020 financial results according to which PHUN stock recorded $10.0 million net revenue in 2020. Revenue from the MaaS platform totaled $9.1 million for PHUN in 2020. Gross margin was 66.4% in 2020 while net loss and net loss per share were $22.2 million and $0.50, respectively.

    In the fourth quarter of 2020, earnings per share fell by 20% while the revenue was reduced by 24.93% as compared to the same period of the prior year to drop at $2,018,000 and missed the estimate of  $3,200,000.

    Conclusion:

    Investors are responding to the news of PHUN stock related to authorization of Bitcoin purchase by the board of directors of Phunware. Management is focused on the adoption of cryptocurrencies as well as providing blockchain services to various enterprises. Financial results of PHUN stock showed a declined growth in terms of its revenue. In a nutshell, deep fundamental and technical analysis is necessary before adding PHUN stock to the portfolio.

  • Why Teligent, Inc. (TLGT) stock is falling today?

    Why Teligent, Inc. (TLGT) stock is falling today?

    Shares of Teligent, Inc. (TLGT) stock were down today after rising  12.52% in the last trading session. TLGT stock price saw a downtrend of  4.27% to drop at  $0.6725 a share at the time of this writing. Let’s deep dive to understand the reason behind this fall.

    What’s happening?

    Teligent, Inc. is a pharmaceutical company working on the development, manufacturing, marketing, and selling of a variety of pharmaceutical products in the United States and Canada. There is no Teligent specific news to explain the reason behind this fall today. Even we find no news, earnings report, analyst downgrades, or shrank targeted per share price in the whole of March to connect with this fall. This is spreading curiosity among investors who are eager to hear some specific related to TLGT stock. So, it is better to look at some previous recent events of Teligent.

    February 2021 Events:

    Teligent, in February 2021, announced the new appointments in a couple of its management positions. On February 23, 2021, TLGT appointed Carter Pate to its Board of Directors. Mr. Pate is serving on the Board of Directors at various other companies and currently holding the responsibilities of Audit and Nominating and Corporate Governance Committees in Teligent.

    On February 16, 2021, William S. Marth, an industry expert, joined Teligent as a member of its Board of Directors. Mr. Marth has experience of 25 years in the pharmaceutical companies as well as manufacturing industries.

    Financial View of TLGT stock:

    • According to the third-quarter results, TLGT stock generated 14.3 million revenue which was 6% higher than the previous quarter due to the high demand for topical products in the U.S.Gross profit of TLGT stock reduced to $0.1 million from $2.4 million in the second quarter of 2020 due to additional expenses related to inventory reserves and other write-offs.
    • Product development and research expenses surged to $2.4 million while selling, general and administrative expenses were $6.5 million in the third quarter of 2020.
    • Operating losses in the third quarter were $8.8 million while the $0.5 million net loss is observed in the third quarter of 2020.

    Conclusion:

    Things are going against the TLGT stock as far as market sentiment is concerned. It seems that momentum was built in the previous trading session but such rises don’t last for a long time.COVID-19 was a major challenge in the continuity of Telligent’s operations, but the management has performed well over the past year. In a nutshell, it would be better for investors to analyze the nitty-gritty of the TLGT stock before taking any decision.

  • FG Financial Group, Inc. (FGF) stock is rising in Pre-market: Why is it so?

    FG Financial Group, Inc. (FGF) stock is rising in Pre-market: Why is it so?

    Shares of FG Financial Group, Inc. (FGF) stock were continuing the uptrend in Monday’s pre-market trading session after gaining 4.09% at the last closing. FGF stock price saw an uptrend of 14.67% to reach $6.01 a share at the time of this writing. But what made the FGF stock high? Let’s understand more of it.

    What’s happening?

    Although the FGF stock is a hot topic among investors, we find no specific reason to justify this rise. There is no particular activity by the FG Financial Group, no earnings report today as it was released almost two weeks ago, no analyst upgrades or upswing target per share price of FGF stock to explain the reason behind this rally. Sometimes social media hype becomes the driving force behind the rising stock price, but this case also doesn’t support this fact. So, what you need to know in this situation? Let’s look at some recent events of the FGF stock.

    Financial Results of 2020:

    On March 18, 2021, FG Financial Group released Financial 2020 results according to which net loss of FGF stock attributed to its common shareholders was $23.9 million while General and administrative expenses were  $6 million in 2020. Non-cash losses related to change in fair value of the FG Financial Group’s investment of  $16.2 million in the common stock of FedNat Holding mainly attributed to a net loss of FGF stock in addition to the loss of $2.1 million which was due to the transfer of 330,231 FNHC shares in connection to Share Repurchase and Cooperation Agreement with Hale Partnership Capital Management, LLC.

    At the end of the year 2020, Financial Group had cash and cash equivalents of $12.1 million and the value of equity securities was down to $8.5 million as compared to $9.1 million at the end of 2019.

    About FG Financial Group:

    FG Financial Group, Inc is currently operating as the reinsurance and investment management holding company in the U.S.Besides specialty property and casualty products, FGF also the provider of services related to strategies, administration, and support.FG Financial Group was founded in 2012 and its headquarters is in St. Petersburg, Florida.

    Conclusion:

    FGF stock is continuing the rising trend so far despite the absence of any FGF news. Such rise usually doesn’t remain for long, but we can’t deny the fact that the stock market is unpredictable, and no one can predict the exact outcome. Such things affect the short-term investors but investors having long-term effects usually focus on the company fundamentals, strategies, and long-term growth.

  • Why Delcath Systems, Inc. (DCTH) stock is falling today?

    Why Delcath Systems, Inc. (DCTH) stock is falling today?

    Delcath Systems, Inc. (DCTH) announced its fourth-quarter 2020 results after which the DCTH stock price happened to be down by 24.54% to drop at $12.28 a share as of this writing. At the previous trading session, DCTH stock was performing well and gained 1.37% at closing. Let’s understand more about the current scenarios.

    Fourth Quarter 2020 Results:

    • DCTH stock product revenue reduced to $379 thousand in the fourth quarter of 2020 as compared to $398 thousand in the same quarter of the previous year.
    • Selling, general and administrative expenses increased by $2.4 million to reach $4.5 million in the last three months of 2020 as compared to $2.1 in the same period of 2019.R&D expenses showed no change and were totaled $2.7 million.
    • Operating expenses surged to $7.3 million while these were $4.8 million in the same period of 2019.
    • DCTH suffered a net loss of $7.0 million in the fourth quarter of 2020 while it recorded a net income of $12.5 million in the same period of 2019.
    • DCTH stock had cash, cash equivalents, and restricted cash of $28.8 million as of 31 December 2020 and it used  $4.6 million cash in its operating activities during the last three months of 2020 while this cash was recorded as $5.4 million for operational activities of 2019.

    Business Highlights in last three months:

    • Delcath Systems was performing phase three FOCUS Clinical Trial of HEPZATO in patients suffering from Metastatic Ocular The results were positive and above expectations. This preliminary analysis includes 87% of patients and final results are expected to come soon in the future.
    • DCTH started consulting engagement for the selection of a portfolio of follow-on-indications in order to increase HEPZATO Kit and CHEMOSAT platform value.
    • DCTH stock completed a public offering of shares of its common stock which resulted in gross proceeds of $22.2 million.
    • Gerard Michel was appointed as the Chief Executive officer by the Delcath stock while Kevin Muir was assigned the role of Vice President for commercial

    Conclusion

    Things are going against the DCTH stock after the earnings release by Delcath Systems. Product revenue was reduced in 2020 while expenses were increased over the year. It would be interesting to see how new management would drive Delcath in the future.

  • Athersys, Inc. (ATHX) stock Rises in Pre-Market: Let’s find out why.

    Athersys, Inc. (ATHX) stock saw a more push in today’s pre-market trading session after the spread of the news that Athersys partner HEALIOS K.Khas completed the enrollment in the ONE-BRIDGE study in Japan. ATHX stock price saw an uptrend of  3.66% to reach $1.70 a share at the time of this writing. ATHX stock seemed green at the previous trading session and closed with a 1.86% gain. Let’s understand the current happenings.

    The ONE-BRIDGE study:

    One Bridge Study suggests the evaluation of the MultiStem® (invimestrocel) in patients who are suffering from acute respiratory distress syndrome (ARDS) which is mainly caused by pneumonia. One Bridge study comprises two patient groups. One group includes 30 patients who are suffering ARDS due to pneumonia. The second group consists of 5 patients suffering from ARDS due to COVID-19. The main objective is to compare the results of the safety and efficacy of Multistem treatment in both groups.HEALIOS will analyze this data after the follow-up period and then further announce the results.

    Athersys is conducting its study named MACOVIA in the united states in order to analyze the results of Multstem against the treatment of COVID-19 induced ARDS patients. One thing is to remember that FDA had given both Fast Track and Regenerative Medicine Advanced Therapy approval to the ARDS program.

    Financial View of ATHX stock

    ATHX announced its fourth quarter and fiscal year 2020 results in which ATHX stock generated $1.3 million in the last three months of 2020 as compared to the same period in 2019 while full-year revenue decreased to $1.4 million as compared to $5.6 million revenue in 2019.R&D expenses increased significantly to $18.7 million in the fourth quarter of 2020 as compared to $7.6 million in the prior year while overall R&D expenses for the full year 2020 reached $63 million as compared to $39 million in 2019. General and administrative expenses of ATHX stock were $4.3 million in the last three months while these were $15.9 for the full year of 2020.

    As of December 31, 2020, Athersys stock had 51.5 million in cash and cash equivalents while these were $35.0 million on December 31, 2019.

    Conclusion:

    It seems that momentum was already built for ATHX stock in the previous trading session and recent news of ATHX stock has added more hype to it. The earnings report suggests that Athersys contract revenue from its collaboration with Healios has decreased over the year, but operational expenses show that ATHX stock has progressed over the year. In a nutshell, investors should analyze ATHX stock both fundamentally and technically.

  • China SXT Pharmaceuticals, Inc. (SXTC) stock gains in Pre-Market. Let’s find out why.

    China SXT Pharmaceuticals, Inc. (SXTC) stock gains in Pre-Market. Let’s find out why.

    Shares of China SXT Pharmaceuticals, Inc. (SXTC) stock remained high in Monday’s pre-market trading session. SXTC stock was up by 33.33% to reach $2.44 a share at the time of this writing. It seems that SXTC stock was performing well in the previous trading session as it was up by 3.39% at the previous closing. But what made the stock high? Let’s deep dive to understand this bull.

    What’s happening?

    Sometimes nothing is good for everything and the same is the situation for SXTC stock. There is no particular activity by the China SXT stock, no press release today, no analysts’upgrades, or upswing targeted per share price of SXTC stock to support the rising stock price of China SXT. However it seems that sympathy play might be the driving force behind this bull as China Pharma Holdings, Inc has skyrocketed over 200% in pre-market session today in response to its fiscal year 2020 results.

    Recent Development

    Back on February 19, China SXT announced the approval of a 1 for 4 reverse split of its ordinary shares by its board of directors. These split-adjusted ordinary shares of SXTC began to trade on February 22, 2021. In connection with this announcement, shareholders of China SXT stock received one new share for every four shares which they owned. As of February 18, China SXT had approximately 62,057,584 outstanding ordinary shares which reduced to 15,514,396 approximately after the reverse split.

    Here is what you need to know about China SXT Pharmaceuticals, Inc.

    • China SXT is mainly operating in the fields of research, development, manufacturing, and marketing of its traditional Chine medicine piece tablets in the Republic of China. SXTC stock has a current market cap of 28.391M.
    • China SXT is a well-established company that provided services to 116 pharmaceutical companies, served 56 pharmacies and 76 hospitals as of May 2020.
    • Feng Zhou, a graduate of Pla National Defense University, is the Chief Executive Officer of the SXTC.
    • China SXT Pharmaceuticals was founded in 2005 and its headquarters are in Taizhou, China.

    Conclusion

    Things are going in favor of SXTC stock as far as market sentiment is concerned but no one knows how long this trend will continue in the future. There is no update about the earnings report so far by the China SXT. In a nutshell, investors should keep an eye on this stock.

  • Why Evofem Biosciences, Inc. (EVFM) stock is falling today?

    Evofem Biosciences, Inc. (EVFM) announced the public offering of its common stock after which the EVFM stock price saw a downtrend of 21.03% today to drop at $1.84 as of this writing. EVFM stock was down by 9.34% at the previous closing. So what you need to know now?

    Public Offering of EVFM Common Stock

    Evofem Biosciences, Inc. (EVFM) is a biopharmaceutical company mainly focused on women’s sexual and reproductive health through the development and commercializing of its various products. EVFM stock recently announced the offering of  17,142,857 shares of its common stock at $1.75 per share public price. Underwriters are granted a 30-day option to buy up to additional 2,571,428 shares worth $4.5 million of Evofem common stock at the public offering price less than the underwriting discounts and commissions. $30 million gross proceeds are estimated for this offering without deducting the underwriting discounts, commissions, and other related expenses. The offering will end on March 29, 2021.

    EVFM is planning to use the net proceeds resulted from this offering in various areas including the commercialization of Phexxi (lactic acid, citric acid, and potassium bitartrate) a contraceptive vaginal gel for the prevention of pregnancy, in the united states of America. Furthermore, these net proceeds will support the advertising activities across television as well as streaming and digital channels of Evofem. Some part of these net proceeds will help in the continuation of phase 3 clinical analysis of EVOGUARD and its related activities in which EVFM is observing the EVO100 for the prevention of infections that transmit sexually.

    “Get Phexxi”: A Marketing campaign

    Evofem started the “Get Phexxi” campaign on Valentine’s day via television, streaming, and digital channels that achieved significant results according to the EVFM officials. The campaign resulted an increase of 73% in ex-factory sales of Phexxi in February 2021 and these sales of the first quarter of 2021 exceeded the full-year sales level of 2020 by March 12. Evofem stock distributed 2,400 Phexxi units in February 2021 which is 30% higher than the prior month.

    Conclusion

    The penny EVFM stock price is continuing the downtrend in the stock market today following the public offering of shares of its common stock and no one knows how long this bearish sentiment will continue. Though EVFM got significant results in its marketing campaign of Phexxi still more development is required for future growth.

  • IMAC Holdings, Inc. (IMAC) stock is falling today. Things you need to know

    IMAC Holdings, Inc. (IMAC) is an orthopedic treatment provider in medical advancements and care regeneration centers in the U.S. IMAC stock saw a downtrend of 5.78% today to drop at $1.63 a share as of this writing. IMAC Holdings recently announced the pricing of the public offering of its common stock. Let’s deep dive to explore more of it.

    What’s happening?

    IMAC has announced a public offering price of $1.60 per share for 10,625,000 shares of its common stock for gross proceeds of $17.0 million. The net proceeds are estimated to be approximately $16.0 million after deducting underwriting discounts. The IMAC holdings along with its co-founder and chief operating officer have the grant of 45-day option to buy up to 15% shares of its common stock under this offering. The offering will close probably on March 26, 2021.

    IMAC stock is planning to use the net proceeds to meet the expenses related to the acquisition of medical clinics and in the launching of its healthcare clinics, to finance outstanding promissory notes, to meet expenses related to the development of new potential treatments in the future, and for general corporate purposes.

    A Financial look at IMAC stock

    In the first week of March 2021, IMAC stock reported its 2020 financial results in which IMAC recorded total net patient revenue of $12.8 million in the fourth quarter which was 15% less than the $15.1 million of prior year.Net loss was decreased to $5.0 million or $0.45 per share of IMAC as compared to a net loss of $6.5 million or $0.84 per share of IMAC in the same quarter of the previous year.IMAC Holdings had $2.6 million cash at the end of the fourth quarter while it was $0.4 million in 2019.

    Conclusion:

    The penny IMAC stock is still gloomy today in the stock market. Companies like Pfizer and Johnson & Johnson have greatly attracted investors due to the development of the COVID-19 vaccine and the companies working on other ailments have suffered to some extent. In a nutshell, individuals eyeing IMAC stock have to research its balance sheet, fundamentals, and growth prospects before taking any step.